Medical/Pharmaceuticals

Frost & Sullivan Recognizes Validic™ as the North America Customer Value Leader in the Remote Patient Monitoring Market

SANTA CLARA, California, Sept. 4, 2019 /PRNewswire/ -- Based on its recent analysis of the North American remote patient monitoring (RPM) market, Frost & Sullivan recognizesValidic™ with the 2019 North America Customer Value Leadership Award for best meeting the current and future market needs fo...

2019-09-04 21:00 849

IDTechEx Research: The Future of Wearables is Medical

BOSTON, Sept. 4, 2019 /PRNewswire/ -- Wearable technology and medical devices have many prominent synergies. Electronic devices on the body are perfectly placed for sensors to collect data relevant to healthcare, with communication options allowing them to be the gateway to digital health data. C...

2019-09-04 10:00 1255

WuXi AppTec Launches DNA Encoded Library (DEL) Service Package "DELight" to Expedite Early Drug Discovery

SHANGHAI and BOSTON, Sept. 3, 2019 /PRNewswire/ -- WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing cost-effective and efficient hit finding services to expedite early drug discovery and bring new medicines to patients faster. DELigh...

2019-09-04 08:00 1096

Porsolt Increases Its Drug Discovery Service Capabilities With the Recent Expansion of Its Research Facility

LAVAL, France, Sept. 4, 2019 /PRNewswire/ -- Porsolt SAS, a long established preclinical screening, efficacy, and safety CRO, has completed a significant expansion of its research facility, adding a further 5,500 sq.ft. of experimental space.     The expansion integrates Porsolt's new areas of...

2019-09-04 00:03 1221

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to Prepare NDA Filing in Europe

BASEL, Switzerland, Sept. 3, 2019 /PRNewswire/ -- Strekin AG (www.strekin.com ), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totalingCHF 2.82 Million from private investors. These funds will enable ...

2019-09-03 14:00 1623

Polpharma Biologics Announces Global Commercialization Deal for Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine

GDAŃSK, Poland, Sept. 3, 2019 /PRNewswire/ -- Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. The medicine is currently in Phase III clinical development for the treatment of re...

2019-09-03 13:15 1539

The First Asia Pacific Psychiatry Symposium Takes Place

SHANGHAI, Sept. 3, 2019 The first-ever Asia Pacific Psychiatric Conference hosted by the Luye Pharma Group recently took place inNanjing. Dozens of psychiatrists and experts from 8 countries and regions includingChina, Korea, Malaysia, and Thailand gathered at the conference to hold discussions o...

2019-09-03 13:11 1445

The First Asia Pacific Psychiatry Symposium Takes Place

NANJING, China, Sept. 3, 2019 /PRNewswire/ -- The first-ever Asia Pacific Psychiatric Conference hosted by the Luye Pharma Group recently took place in Nanjing. Dozens of psychiatrists and experts from 8 countries and regions includingChina, Korea, Malaysia, and Thailand gathered at the conference...

2019-09-03 12:44 1514

International Atherosclerosis Society & Residual Risk Reduction Initiative Publish Consensus Statement on New Treatment for Residual Cardiovascular Risk

MILAN and BASEL, Switzerland, Sept. 3, 2019 /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, accordin...

2019-09-03 07:44 1296

Children's Lives Will Be Saved Due to Invention of Simple Water Treatment System "Aquatabs Flo"

WEXFORD, Ireland, Sept. 2, 2019  /PRNewswire/ -- The world famous medical journalThe Lancet has published the results of a two year health impact trial in Bangladesh. Less than 5% of studies submitted to this peer reviewed journal are published.  

2019-09-02 21:59 1414

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

SHANGHAI, Aug. 30, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation...

2019-08-31 10:54 1723

Syntellix Asia and Chunli Agree Far-reaching Co-operation to Introduce and Market Innovative "Quantum Leap in Implantology" MAGNEZIX® Medtech Devices in China

- Milestone contract signed between leading Chinese orthopaedic medtech supplier andSingapore based Asian subsidiary and hub of German world-market and technology leader in the area of bioabsorbable metallic implants for use in orthopaedic and trauma surgery - Contract volume of more than 100 mi...

2019-08-30 22:28 1748

Innovent Biologics Study Results of IBI303 in Patients with Ankylosing Spondylitis was Published in "The Lancet Rheumatology"

SUZHOU, China, Aug. 30, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical trial results of IBI303, an anti-tumor necrosis factor-alpha (anti-TNF...

2019-08-30 17:38 2440

Concept Medical Inc. Granted 'Breakthrough Device Designation' From the FDA for Its MagicTouch AVF Sirolimus Coated Balloon

Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, for the treatment of stenotic lesions of Arteriovenous Fistulae or Arteriovenous graft in hemodialys...

2019-08-30 05:05 1670

DarwinHealth Announces Compound-2-Clinic (C2C) Scientific Collaboration with Celgene to Deploy a Quantitative Systems Biology Discovery Platform to Characterize Celgene Oncology Compounds

NEW YORK, Aug. 30, 2019 /PRNewswire/ -- DarwinHealth today announced a multi-year scientific research collaboration with Celgene Corporation ("Celgene") to use quantitative systems biology-based algorithms, technologies that also underpin NY State CLIA-approved diagnostic tests in oncology, and ...

2019-08-30 01:59 1828

Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India

WETTEREN, Belgium, Aug. 29, 2019 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, announced today its intention to purchase the remaining 50 percent ownership interest in its Visakhapatnam,In...

2019-08-29 20:04 1703

Luye Pharma First Half of 2019 Results: Strong Revenue Growth and Substantial Development of R&D Product Pipelines

SHANGHAI, Aug. 29, 2019 /PRNewswire/ -- Luye Pharma Group (02186.HK) released its financial results for the first half of 2019 onAugust 28. The results show the company has achieved a revenue ofRMB 3.131 billion, up 42.1% year-on-year; EBITDA reachedRMB 1.263 billion, up 44.1% year-on-year, while...

2019-08-29 16:34 11035

Taiho Pharmaceutical Invests in New Venture Capital Fund

TOKYO, Aug. 29, 2019 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director:Masayuki Kobayashi) announced on August 29 that the company has entered into an agreement to invest up toUS$30 million in Remiges Biopharma Fund II, LP a biopharma venture capital...

2019-08-29 13:00 1343

Viva Biotech Announces 2019 Interim Results

Financial Highlights * Revenue grew significantly by 83.9% YoY from RMB77.4 million to approximatelyRMB142.3 million. * Gross profit recorded approximately RMB71.9 million, growing significantly by 70.0% fromRMB42.3 million. * Net profit excluding extraordinary profit or loss increased sig...

2019-08-29 11:12 4238

Innovent Reports Interim Results for Fiscal Year 2019

SUZHOU, China, Aug. 29, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced its interim financial results for the six months endedJune 30, 2019. HIGHLIGHTS AND OTH...

2019-08-29 08:39 1701
12345678 ... 344